Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Purchased by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lifted its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 48.9% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 673,289 shares of the company’s stock after acquiring an additional 221,196 shares during the period. Assenagon Asset Management S.A. owned 1.45% of Pacira BioSciences worth $16,731,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. ProShare Advisors LLC boosted its position in shares of Pacira BioSciences by 30.2% during the 4th quarter. ProShare Advisors LLC now owns 16,003 shares of the company’s stock valued at $301,000 after purchasing an additional 3,710 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Pacira BioSciences by 16.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 502,204 shares of the company’s stock valued at $9,462,000 after purchasing an additional 70,307 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Pacira BioSciences by 3.1% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,077 shares of the company’s stock valued at $491,000 after purchasing an additional 794 shares during the last quarter. LPL Financial LLC acquired a new stake in shares of Pacira BioSciences in the fourth quarter worth $251,000. Finally, Norges Bank bought a new position in Pacira BioSciences in the fourth quarter worth $2,405,000. Institutional investors own 99.73% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Wall Street Zen raised Pacira BioSciences from a “hold” rating to a “buy” rating in a report on Friday, June 6th. Barclays lifted their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a report on Friday, February 28th. Needham & Company LLC cut their target price on Pacira BioSciences from $32.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Finally, HC Wainwright increased their price target on Pacira BioSciences from $48.00 to $65.00 and gave the company a “buy” rating in a research note on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $26.44.

Insider Buying and Selling

In other news, SVP Lauren Riker sold 5,578 shares of the business’s stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $26.21, for a total transaction of $146,199.38. Following the completion of the sale, the senior vice president now owns 59,564 shares in the company, valued at $1,561,172.44. The trade was a 8.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 6.40% of the stock is owned by insiders.

Pacira BioSciences Stock Performance

Shares of PCRX stock opened at $24.24 on Friday. The business’s 50-day moving average price is $25.56 and its 200-day moving average price is $23.58. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of -11.94 and a beta of 0.52. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $29.61.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.